ASCENTAGE-B (06855) will present four latest clinical advances at the American Cancer Research Association Annual Meeting in 2026.

ASCENTAGE-B (06855) announces that four preclinical research advancements from the company have been selected for the 2026 American Association for Cancer Research (AACR) Annual Meeting. The conference will be held in San Diego, California, USA from April 17th to April 22nd, 2026. The data to be presented at the meeting will cover three products from the company, including the novel BCR-ABL inhibitor Orlotinib (trade name: Nairik; research code: HQP1351), the FAK/ALK/ROS1 triple kinase inhibitor APG-2449, and the EED inhibitor APG-5918. The AACR Annual Meeting is an important platform for advancing the field of oncology, where scientists, clinicians, healthcare professionals, cancer survivors, patients, and advocates come together to share and discuss the latest breakthroughs in cancer research. From population science and prevention, to cancer biology, translational medicine, and clinical research, to survivorship care and advocacy, the AACR Annual Meeting showcases cutting-edge advancements in cancer science and medicine.